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Background/Aims: Concurrent chemoradiotherapy (CCRT) 
is considered the treatment option for locally advanced pan-
creatic cancer, but accompanying gastrointestinal toxicities 
are the most common complication. With the introduction 
of three-dimensional conformal radiotherapy (3-D CRT) and 
intensity-modulated radiotherapy (IMRT), CCRT-related ad-
verse events are expected to diminish. Here, we evaluated 
the benefits of radiation modalities by comparing gastroin-
testinal toxicities between 3-D CRT and IMRT. Methods: Pa-
tients who received CCRT between July 2010 and June 2012 
in Severance Hospital, Yonsei University College of Medicine, 
were enrolled prospectively. The patients underwent upper 
endoscopy before and 1 month after CCRT. Results: A total 
of 84 patients were enrolled during the study period. The 
radiotherapy modalities delivered included 3D-CRT (n=40) 
and IMRT (n=44). The median follow-up period from the start 
of CCRT was 10.6 months (range, 3.8 to 29.9 months). The 
symptoms of dyspepsia, nausea/vomiting, and diarrhea did 
not differ between the groups. Upper endoscopy revealed sig-
nificantly more gastroduodenal ulcers in the 3-D CRT group 
(p=0.003). The modality of radiotherapy (3D-CRT; odds ratio 
[OR], 11.67; p=0.011) and tumor location (body of pancreas; 
OR, 11.06; p=0.009) were risk factors for gastrointestinal 
toxicities. Conclusions: IMRT is associated with significantly 
fewer gastroduodenal injuries among patients treated with 
CCRT for pancreatic cancer. (Gut Liver 2016;10:303-309)
Key Words: Gastrointestinal toxicities; Chemoradiotherapy; 
Pancreatic neoplasms; Endoscopy; Radiotherapy, intensity-
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INTRODUCTION
Concurrent chemoradiotherapy (CCRT) can be a treatment 
option for locally advanced pancreatic cancer (LAPC).1,2 Since 
complete surgical resection is the only curative treatment, a vast 
majority of research has been targeted for treatments that could 
change the status of nonoperable pancreatic cancer to that of 
operable. Although some issues remain under debate, preopera-
tive CCRT is currently being extended to resectable and bor-
derline resectable pancreatic cancer.3-6 This treatment improves 
local control and resectability, and increases the possibility of 
R0 resection.7,8 However, as the stomach and small bowel are 
located close to the pancreas, both organs are included in the 
radiation field. CCRT-related gastrointestinal (GI) toxicities are 
major dose-limiting factors.9-11 Acute toxicities include nausea, 
vomiting, diarrhea, abdominal pain, and bleeding. Late toxicities 
related with radiotherapy are obstruction, stricture, and fistula 
formation.10,12 These toxicities tend to lower the patient’s quality 
of life and can even delay treatment of pancreatic cancer, thus 
decreasing the chance of surgery.
With technological improvements in radiotherapy, the deliv-
ery modality has evolved from conventional to three-dimen-
sional conformal radiotherapy (3-D CRT). Recently developed 
intensity-modulated radiotherapy (IMRT) allows a combination 
of variable radiation intensity and 3-D radiation treatment 
planning. IMRT is therefore superior to 3-D CRT in maximiz-
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ing homogeneous radiation to the planned target volume, while 
minimizing the damage to adjacent normal tissues.13,14 Helical 
tomotherapy (HT) is a type of IMRT that allows for adjust-
ment of the planned target volume using real-time treatment 
monitoring by diagnostic computed tomography (CT) systems.15 
However, there have been no randomized trials comparing 
IMRT and 3-D CRT in terms of GI toxicities and other outcomes. 
In this study, we compared the outcomes of IMRT and 3-D CRT, 
using GI toxicities, including endoscopic findings, as the end 
point.
MATERIALS AND METHODS
1. Patients
The patients who received CCRT for treatment of borderline 
resectable pancreatic cancer and LAPC at Severance Hospital 
in Seoul, Korea, between July 2010 and June 2012 were pro-
spectively enrolled. The enrollment criteria were pathologically-
proven pancreatic adenocarcinoma, age over 20 years and an 
Eastern Cooperative Oncology Group performance status of 0 to 
1. The excluded patients were who had received chemotherapy 
or surgery before CCRT and advanced pancreatic cancer. The 
patients who were taking proton pump inhibitor were excluded 
but GI medication such as antiemetic and prokinetic drugs were 
allowed. The patients who had not completed their scheduled 
radiation therapy were also excluded from per-protocol analy-
sis. All patients participating in this study provided informed 
consent. This trial was approved by the Institutional Review 
Board for Human Research at Severance Hospital (4-2011-0594). 
2. Staging
All patients underwent dynamic CT scans and tumors were 
classified as resectable, locally advanced or advanced pancreatic 
cancer using the American Joint Committee on Cancer (seventh 
edition) TNM staging system. Borderline resectable pancreatic 
cancer was defined as tumor abutment of the superior mesen-
teric artery involving less than 180 degrees of the circumference 
of the artery, severe unilateral superior mesenteric vein and por-
tal vein impingement and gastroduodenal artery encasement up 
to origin at the hepatic artery.16
3. Chemotherapy
The regimens of chemotherapy were gemcitabine- or 5-fluo-
rouracil (5-FU)-based: (1) 1,000 mg/m2 of gemcitabine on days 
1, 8, and 15 of a 4-week regimen; (2) 1,000 mg/m2 of 5-FU on 
days 1 to 3 of a 4-week regimen intravenously, or 0.5 g tega-
fur-uracil (UFT) three times per day orally until radiotherapy 
ended. Theses chemotherapy regimens were decided by Korean 
insurance standards. The response of treatment was evaluated 
1 month after the end of chemoradiotherapy, according to the 
Response Evaluation Criteria in Solid Tumors. We continued 
combination therapy of gemcitabine and cisplatin for those who 
were unable to undergo surgery. The chemotherapy schedule 
was as following: 1,000 mg/m2 of gemcitabine on days 1, 8, and 
15 and 70 mg/m2 of cisplatin on day 1 of a 4-week regimen in-
travenously.
4. Radiotherapy
The radiotherapy modalities of CCRT were either 3-D CRT 
using a 10-MV linear accelerator or IMRT using HT (Accuray, 
Sunnyvale, CA, USA). For IMRT, the patients received a respira-
tion education to reduce intrafractional respiratory motion and 
to increase patient’s set up accuracy. Additionally, the BodyFIX 
immobilization device (Medical Intelligence, Schwabmunchen, 
Germany) with a total body cover sheet and a full-body vacu-
um-locking bag was applied. When four-dimensional CT simu-
lation was performed, intravenous contrast material and diluted 
oral gastrografin were applied precisely to delineate organs at 
risk in GI tract. We defined the gross tumor volume (GTV) as the 
primary tumor and involved regional lymph nodes. We defined 
the planning target volume (PTV) as the GTV plus a 5-mm mar-
gin. We applied a smaller margin if the adjacent duodenum was 
abutting GTV. For planning of IMRT, we used HT Hi-Art System 
version 2.0 (TomoTherapy Inc., Madison, WI, USA).17 At least 
95% of the GTV must be covered by the prescription dose, and 
the maximal dose to contiguous 2 mL of duodenum was limited 
to 50 Gy (equivalent dose in 2 Gy), similar to 3-D CRT cases. 
The median fraction and total doses were 2.54 Gy (range, 2.5 to 
2.85 Gy) and 58.42 Gy (range, 50 to 62.5 Gy), respectively. For 
3-D CRT, GTV and PTV were also defined such as IMRT. The 
field arrangement was a three-field technique, which consisted 
of opposed laterals and an anteroposterior field or a four-field 
box technique. A total dose of 45 or 50.4 Gy was delivered in 
daily fractions of 1.8 Gy.18 3-D CRT and IMRT were performed 
5 days per week. The patient decided the radiotherapy modality 
after detailed explanation by a radiology oncologist. CCRT was 
proceeded on weekdays. 
5. GI toxicities
All patients underwent upper endoscopy before and 1 month 
after CCRT. The upper endoscopy was conducted by a board-
certified endoscopist and the result was verified by another 
board-certified endoscopist. Any patients with gastroduodenal 
ulcers at initial endoscopic findings were excluded. The patients 
were asked about any CCRT-related symptoms every week 
during radiotherapy in the outpatient department. After CCRT 
ended, patients were followed up once per month. CCRT-related 
GI symptoms included dyspepsia, nausea, vomiting, and diar-
rhea. GI toxicities were classified according to the National Can-
cer Institute Common Terminology Criteria for Adverse Events 
version 4.0. In our study, radiation-induced injuries observed 
with endoscopy were defined as telangiectasia, diffuse erythema 
of mucosa, ulcers, and scar formation.19 All patients with symp-
toms or signs of ulceration in endoscopic findings received 
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proper medical treatments.
6. Statistical analysis
The Pearson chi-square test was used to compare the treat-
ment results and GI toxicity between 3D-CRT and IMRT. The 
Kaplan-Meier method and log-rank tests were used to compare 
overall survival (OS) between 3-D CRT and IMRT. To determine 
risk factors of GI toxicity, we used logistic regression for multi-
variate analysis.
All analyses were performed using statistical software SPSS 
version 17 (SPSS Inc., Chicago, IL, USA). p-values less than 0.05 
indicated statistical significance. 
RESULTS
1. Patient characteristics
A total of 84 patients were enrolled in this study. Forty pa-
tients underwent 3-D CRT and 44 patients received IMRT. The 
median follow-up was 10.6 months (range, 3.8 to 29.9 months). 
The 3-D CRT and IMRT groups showed similar baseline charac-
teristics, with the exception of chemotherapy regimen (Table 1). 
The IMRT group was more likely to have received gemcitabine 
than the 3-D CRT group (p<0.001).
2. Comparison of treatment results and OS 
The treatment response was evaluated 1 month after the end 
of CCRT and the operability was also re-evaluated at the time 
(Table 2). Thirteen patients were downstaged and underwent 
surgery. R0 resection was performed in all patients. In the IMRT 
group, 10 patients (23.8%) were downstaged and in 3-D CRT 
group, three patients (9.1%) were downstaged and underwent 
surgery, but the difference was not significant (p=0.095). The 
IMRT group showed significantly better OS than the 3-D CRT 
group, with a mean OS of 22.6 months compared with 15.8 
months, and 1-year OS of 84% compared with 58%, respec-
tively (p=0.006) (Fig. 1). 
3. GI toxicities 
The overall incidence of GI toxicities, including dyspepsia, 
nausea/vomiting, and diarrhea, was similar between the two 
groups (Table 3). There was no incidence of grade 3 to 4 toxic-
ity. Out of a total of 84 patients, 59 patients (70.2%) underwent 
follow-up upper endoscopy 1 month after the end of CCRT. 
There were no patients with gastric or duodenal ulcers at the 
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Fig. 1. Comparison of overall survival according to radiation modality. 
IMRT, intensity-modulated radiotherapy; 3-D CRT, three-dimensional 
conformal radiotherapy.
Table 1. Baseline Characteristics
Characteristic 3-D CRT (n=40) IMRT (n=44) p-value
Age, yr 64.3±10.3 61.5±9.5 0.137
Sex 0.932
    Male 24 (60) 26 (59.1)
    Female 16 (40) 18 (40.9)
Hypertension  17 (42.5) 15 (46.9) 0.428
Diabetes mellitus 12 (30) 12 (27.3) 0.782
Stage 0.122
    Borderline resectable 10 (25) 18 (40.9)
    Locally advanced 30 (75) 26 (59.1)
Tumor location 0.517
    Head 24 (60) 29 (65.9)
    Body  13 (32.5) 14 (31.8)
    Tail  3 (7.5)  1 (2.3)
Chemotherapy regimen 0.001
    Gemcitabine 18 (45) 39 (88.6)
    5-FU 22 (55)  5 (11.4)
Tumor size, cm 3.6±1.1 3.4±1.1 0.408
CA 19-9, U/mL 1,032.7±2,194.4 1,327.8±2,145.7 0.535
CEA, ng/mL 5.7±9.5 8.6±15.6 0.314
Hemoglobin, g/dL 13.1±1.6 13.4±1.3 0.550
Data are presented as mean±SD or number (%).
3-D CRT, three-dimensional conformal radiotherapy; IMRT, intensity-
modulated radiotherapy; 5-FU, 5-fluorouracil; CA 19-9, carbohydrate 
antigen 19-9; CEA, carcinoembryonic antigen.
Table 2. Comparison of Treatment Results according to Radiation 
Modality
3-D CRT (n=40) IMRT (n=44) p-value
Treatment response 0.216
    PR-SD 25 (62.5) 33 (75.0)
    PD 15 (37.5) 11 (25.0)
Treatment after CCRT 0.095
    Surgery 3 (9.1) 10 (23.8)
    Chemotherapy 30 (90.9) 32 (76.2)
Data are presented as number (%).
3-D CRT, three-dimensional conformal radiotherapy; IMRT, intensity-
modulated radiotherapy; PR-SD, partial response–stable disease; PD, 
progressive disease; CCRT, concurrent chemoradiotherapy. 
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initial endoscopic examination. However, in the follow-up en-
doscopy, the IMRT group showed a significantly lower incidence 
of gastroduodenal ulceration compared to the 3-D CRT group 
(p=0.003). GI bleeding or perforation was not observed during 
the follow-up period in either group. The tumor location (body 
of pancreas; odds ratio [OR], 11.06; p=0.009) and 3-D CRT (OR, 
11.67; p=0.011) were independent risk factors of GI toxicity 
(Table 4). 
DISCUSSION
CCRT was first attempted for LAPC by the Gastrointestinal 
Tumor Study Group (GITSG) in the 1980s.20 Since then, many 
trials have been carried out and have showed promising results, 
but the use of CCRT in pancreatic cancer is still under debate. A 
few large randomized studies were carried out after the GITSG 
study. However, the radiation dose and chemotherapy regimens 
differed. The E4201 study demonstrated a benefit of chemora-
diotherapy over chemotherapy using 3-D CRT and gemcitabine. 
Recently, CCRT is being carried out in resectable and borderline 
resectable pancreatic cancer as a neoadjuvant treatment.21,22 
The rationale for preoperative CCRT includes downstaging of 
tumors, prevention of micrometastasis and selection of those 
patients with early far metastasis during treatment.23,24 Preop-
erative CCRT has thus led to improvement of resectability, R0 
resection and prevention of recurrence after curative surgery. In 
addition, unnecessary surgery can be avoided for those patients 
with early far metastatic pancreatic cancer. 
Table 3. Comparison of Gastrointestinal Toxicity according to Radia-
tion Modality
3-D CRT (n=40) IMRT (n=44) p-value
Dyspepsia 0.442
    Grade 0 31 (77.5) 37 (84.1)
    Grade 1–2 9 (22.5) 7 (15.9)
Nausea/vomiting 0.317
    Grade 0 26 (65.0) 33 (75.0)
    Grade 1–2 14 (35.0) 11 (25.0)
Diarrhea 0.725
    Grade 0 38 (95.0) 41 (93.2)
    Grade 1–2 2 (5.0) 3 (6.8)
Upper endoscopy after CCRT 26 (65.0) 33 (75.0) 0.317
Gastroduodenal ulcers* 0.003
    Grade 0 15 (57.7) 30 (90.9)
    Grade 1–2 11 (42.3) 3 (9.1)
Data are presented as number (%).
3-D CRT, three-dimensional conformal radiotherapy; IMRT, intensity-
modulated radiotherapy; CCRT, concurrent chemoradiotherapy. 
*Gastroduodenal ulcers were evaluated by endoscopy.
Table 4. Univariate and Multivariate Analyses for Risk Factors of Gastrointestinal Toxicity
Variable GI toxicity p-value* OR 95% CI p-value†
Age, yr 0.564
    ≤65 9 (64.3) 1
    >65 5 (35.7) 0.39 0.07–2.03 0.265
Sex 0.200
    Male 6 (42.9) 1
    Female 8 (57.1) 0.36 0.07–1.77 0.209
Tumor location 0.024
    Head of pancreas 6 (42.9) 1
    Body 8 (57.1) 11.06 1.84–66.51 0.009
    Tail 0
Radiation modality 0.003
    IMRT 3 (21.4) 1
    3-D CRT 11 (78.6) 11.67 1.74–78.1 0.011
Chemotherapy regimen 0.184
    Gemcitabine 8 (57.1) 1
    5-FU 6 (42.9) 1.14 0.20–6.41 0.881
Tumor size, cm 0.406
    ≤3.5 8 (57.1) 1
    >3.5 6 (42.9) 0.67 0.13–3.45 0.634
Data are presented as number (%).
GI, gastrointestinal; OR, odds ratio; CI, confidence interval; IMRT, intensity-modulated radiotherapy; 3-D CRT, three-dimensional conformal ra-
diotherapy; 5-FU, 5-fluorouracil.
*Chi-square test was used; †Logistic regression was used.
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The biggest concern associated with CCRT is the complication 
of nearby structures, especially the small bowel and stomach. 
As the pancreas is moderately sensitive to radiotherapy, higher 
doses of radiation are needed and complications are inevitable.25 
Conventional radiotherapy contributed to the high incidence of 
GI toxicity before the early 1990s.26 However, with advance-
ments in radiotherapy, 3-D CRT could reduce GI toxicities by 
using CT images for guidance. IMRT is a more recent modality 
to deliver radiotherapy. IMRT can provide higher and homoge-
neous radiation doses to the target planned volume and mini-
mize toxicities to the adjacent critical structures.7 Yovino et al.12 
showed that the overall incidence of grade 3 to 4 acute GI tox-
icity was low in patients who received IMRT-based CCRT com-
pared to 3-D CRT. However, in our study, there was no grade 
3 to 4 GI toxicity in either the IMRT or 3-D CRT groups. When 
comparing grade 1 to 2 GI toxicity between treatment modali-
ties, the symptoms of dyspepsia, nausea/vomiting, and diarrhea 
were not significantly different because most of the patients re-
ceived medications, such as antiemetics, during treatment. How-
ever, the incidence of grade 1 to 2 gastroduodenal ulceration 
was significantly higher in the 3-D CRT group than in the IMRT 
group. The endoscopic findings showed that IMRT could mini-
mize the radiation to organs at risk. Nakamura et al.10 showed 
that the estimated incidence of upper GI bleeding at 1 year was 
about 20% in those patients who received 3-D CRT with weekly 
gemcitabine. In addition, our previous study showed similar GI 
bleeding rate and 24.5% of GI bleedings occurred less than 3 
months after CCRT.9 Based on our previous data, we performed 
upper endoscopy at 1 month after the end of CCRT to evalu-
ate the early events. In this study, there was no incidence of GI 
bleeding during the follow-up period, because the patients who 
showed abnormal endoscopic findings received proper medical 
management, such as a proton pump inhibitor. Late toxicities 
such as obstruction, perforation and fistula, were not found in 
this study.
Until recently, there have been few studies which compare 
the outcomes and OS between IMRT group and 3-D CRT group. 
Combs et al.27 reported the OS and progression-free survival 
were not different in IMRT group and 3-D CRT group. However, 
in our study, the IMRT group showed improved OS compared 
to the 3-D CRT group. Although the objective response and the 
rate of surgery after CCRT were not significantly different, more 
patients who received IMRT seemed to undergo surgery (p=0.095) 
by downstaging the tumor. IMRT allows for delivery of higher 
doses and homogeneous radiation to the planned target volume 
and adjustment of the radiation field in real-time.28 One previ-
ous study that was conducted in our institute demonstrated that 
high-dose HT with concurrent full-dose chemotherapy resulted 
in improved local control and long-term survival in patients 
with LAPC.29 The toxicities were acceptable. Also, full dose of 
gemcitabine was used in this study compared to 300 mg/m2 
of gemcitabine used in Combs study. In our previous studies, 
full-dose gemcitabine based CCRT were treated in LAPC and 
the toxicities were acceptable.29-31 These advantages may delay 
tumor progression by local control and prevent micrometastasis 
of the tumor and lead to better resectability. 
We note that our study had some limitations. Firstly, the 
chemotherapy regimen was significantly different between the 
two groups. Most of the patients in the IMRT group received 
gemcitabine. There are several reports that gemcitabine-based 
chemoradiotherapy is associated with better OS than 5-FU-
based chemoradiotherapy.32,33 Also, in this study, the OS was 
higher in patients with gemcitabine than those with 5-FU/
UFT (20.6 months vs 9.4 months, p<0.001). In Korean medical 
policy, patients receive insurance benefits for 3-D CRT but not 
for IMRT. Thus, administration of chemotherapy depends on the 
radiation modality. Therefore, in the 3-D CRT group, the che-
motherapy regimen was selected based on patients’ economic 
status. Although this study was a prospective cohort trial, the 
chemotherapy regimen could not be unified. Second, the stages 
were not significantly different in both groups, but more LAPC 
patients seemed to be included in the 3-D CRT group. Third, we 
could not compare the dose-volume parameters between two 
modalities, so, in further study, comparison of dose volume pa-
rameters according to radiation modalities and the correlation 
between dose volume parameters and GI toxicities should be 
evaluated.
In conclusion, IMRT-based chemoradiotherapy significantly 
reduced GI toxicities which act as limiting factors for the treat-
ment. In addition, IMRT improved the treatment results of pan-
creatic cancer. Large and well-designed randomized trials are 
needed to decide on a standard radiation modality and chemo-
therapy regimen. 
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